LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease. The authors report a case of a patient treated with a statin, fibrate, ezetimibe, and niacin in whom a calculated low-density lipoprotein cholesterol level of 5 mg/dL was achieved.
Phillips
William
W
Division of Cardiovascular Medicine, University of California Davis, Davis, CA, USA.
Schaefer
Saul
S
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D000069438:Ezetimibe; D011345:Fenofibrate